WHO Establishes Foodborne Disease Collaborating Centre in Belgium as ECDC Warns of Resistant Superbugs and EMA Upgrades Clinical Trial Roles
The World Health Organization designated Belgium's Sciensano institute as a new Collaborating Centre on Foodborne Disease Burden on the same day the ECDC issued its fourth rapid risk assessment on carbapenem-resistant Enterobacterales and the EMA updated CTIS safety role management.
By 全球伯乐 News
Source compilation
On this page
On November 18, 2026, the World Health Organization (WHO) formally designated the Service Health Information within the Epidemiology and Public Health Directorate at Sciensano—Belgium's national scientific institute in Brussels uniting human, animal, and environmental health—as the new WHO Collaborating Centre on Foodborne Disease Burden. On the same day, the European Centre for Disease Prevention and Control (ECDC) in Stockholm published its fourth Rapid Risk Assessment on carbapenem-resistant Enterobacterales (CRE), while the European Medicines Agency (EMA) in Amsterdam rolled out upgraded safety role management and sandbox onboarding for the European Union's Clinical Trials Information System (CTIS)123.

AI-generated editorial illustration: a clear borosilicate Petri dish holding amber agar, unbranded stainless-steel forceps, a miniature glass vial, and a white porcelain bowl on veined white marble symbolize global foodborne disease modeling, antimicrobial resistance genomic surveillance, and clinical trial safety governance, not an actual photograph from the WHO, ECDC, or EMA.
WHO Designates Belgium's Sciensano to Advance Global Foodborne Disease Statistical Modeling
According to the WHO announcement, Sciensano's designation builds on years of close collaboration with the WHO Foodborne Disease Burden Epidemiology Reference Group (FERG). Under its new mandate, the Brussels centre will develop and compute statistical models to estimate the global, regional, and national burden of foodborne illnesses, collect and synthesize epidemiological mortality and morbidity data, assist the WHO in tracking global food safety indicators, and provide hands-on capacity building for Member States conducting national burden-of-disease studies within a One Health framework1.
While statistical modeling strengthens preventative food safety, European hospitals are confronting an accelerating crisis in antimicrobial resistance. In its fourth CRE Rapid Risk Assessment update, drawing on the European Antimicrobial Resistance Genes Surveillance Network (EURGen-Net) and the 2025 CRE survey (CRE25), the ECDC reported a steady epidemiological deterioration across the EU and European Economic Area since its previous assessment in 2023. Most EU/EEA countries recorded a sustained rise in bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae, driving higher clinical mortality and prolonged intensive-care stays2.
ECDC Flags Rising Metallo-Beta-Lactamase Superbugs While EMA Refines Clinical Trial Safety Roles
Crucially, the ECDC genomic evaluation identified two converging biological threats. First, an increasing proportion of Klebsiella pneumoniae isolates now carry New Delhi metallo-beta-lactamase (NDM) carbapenemases, which render several newer beta-lactam/beta-lactamase inhibitor drug combinations approved since 2016 clinically ineffective. Second, surveillance detected a higher prevalence of hypervirulence markers—specifically yersiniabactin and aerobactin—alongside the rapid cross-border spread of Escherichia coli strains carrying the blaOXA-244 gene. The agency urged national health authorities to enforce stringent infection prevention and control protocols, whole-genome sequencing surveillance, and antimicrobial stewardship2.
To support the safe clinical development of next-generation therapeutics across Europe, the European Medicines Agency's November 18 CTIS session detailed major operational refinements under the EU Clinical Trials Regulation (Regulation (EU) No 536/2014). The update introduces dedicated Safety user roles within the CTIS Safety Module to ensure granular, least-privilege access control over pharmacovigilance and adverse-event submissions, alongside a revamped CTIS Training Environment access workflow administered through Test EMA Account Management for commercial and academic trial sponsors3.
Source notes
-
2026-11-18 · New WHO collaborating centre established to support work on foodborne disease burden · World Health Organization (WHO). ↩ ↩2
-
2026-11-18 · Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update · European Centre for Disease Prevention and Control (ECDC). ↩ ↩2 ↩3
-
2026-11-18 · Clinical Trials Information System (CTIS) bitesize talk: CTIS training environment and role management · European Medicines Agency (EMA). ↩ ↩2


